Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.27 0.2 (0.3%) Market Cap: 12.82 Bil Enterprise Value: 12.45 Bil PE Ratio: 40.28 PB Ratio: 2.37 GF Score: 69/100

Q3 2020 Biomarin Pharmaceutical Inc Earnings Call Transcript

Nov 05, 2020 / 09:30PM GMT
Release Date Price: $75.05 (-1.73%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the BioMarin Third Quarter 2020 Financial Results Conference Call. Hosting the conference call today is from BioMarin, Traci McCarty, Vice President of Investor Relations. Please go ahead, ma'am.

Traci McCarty
BioMarin Pharmaceutical Inc. - VP of IR

Thank you, Joanna, and thank you all for joining us today. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and development by competitors, and those factors detailed in BioMarin's filings with the SEC, including 10-Q, 10-K and 8-K reports.

On the call remotely -- well, some are remote

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot